首站-论文投稿智能助手
典型文献
Efficacy and Safety of Mulberry Twig Alkaloids Tablet for Treatment of Type 2 Diabetes:A Randomized,Double-Blind,Placebo-Controlled Multicenter Clinical Study
文献摘要:
Objective:To assess the efficacy and safety of mulberry twig alkaloids(Sangzhi alkaloids,SZ-A)for treatment of type 2 diabetes in a randomized,double-blind,placebo-controlled multicenter clinical trial.Methods:A total of 200 patients were randomized to receive SZ-A(n=100)or placebo(n=100)for 16 weeks.The data analysis system for electronic data capture clinical trial central randomization system was used for randomization and dispensing of drugs.The primary outcome was the change in glycosylated hemoglobin(HbA1c)level.The secondary outcome included the proportions of cases with HbA1c<7.0%and HbA1c<6.5%,fasting blood glucose(FBG),postprandial blood glucose(PBG),area under curve for the PBG(AUC0-2h),body weight,and body mass index(BMI).Adverse events(AEs),severe adverse events(SAEs),treatment-related adverse events(TAEs),gastrointestinal disorders(GDs),blood pressure,routine blood tests,and liver and kidney function were monitored.Results:Compared with baseline,the change of HbA1c at week 16 was-0.80%(95%Cl:-0.98%to-0.62%)and-0.09%(95%Cl:-0.27%to 0.09%)in SZ-A group and placebo group,respectively.The proportion of patients with HbA1c<7%and<6.5%was higher in the SZ-A group than in the placebo group(46.8%vs.21.6%and 29.9%vs.10.8%).The observed values and changes in FBG,1 h-PBG,2 h-PBG,and AUC0-2h differed significantly between groups(P<0.001),but differences were not significant in body weight and BMI(P>0.05).The incidence rates of AEs,TAEs,and GDs differed significantly between groups(P=0.010,P=0.005,and P=0.006,respectively),whereas the incidence rates of SAEs showed no significant differences between groups(P=1.000).Conclusion:SZ-A are effective and safe for treatment of type 2 diabetes.[The protocol was registered in (ChiCTR2000038550)]
文献关键词:
作者姓名:
QU Ling;LIANG Xiao-chun;TIAN Guo-qing;ZHANG Gai-li;WU Qun-li;HUANG Xiu-mei;CUI Ya-zhong;LIU Yu-ling;SHEN Zhu-fang;MA Guo-qing;LU Hao;LI Yi;JIANG Hong;YANG Xi-yan;ZHANG Guang-de;YANG Chen-hua
作者机构:
Department of Traditional Chinese Medicine,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing(100730)China;Institute of Materia Medica,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing(100050),China;Department of Endocrinology,the Second Affiliated Hospital of Heilongjiang University of Chinese Medicine,Haerbin(150001),China;Department of Endocrinology,Shuguang Hospital,Shanghai University of Traditional Chinese Medicine,Shanghai(201203),China;Department of Traditional Chinese Medicine,Beijing Hospital,Beijing(10005),China;Department of Endocrinology,the Second Affiliated Hospital of Liaoning University of Traditional Chinese Medicine,Shenyang(110034),China;Department of Geriatrics,the First Affiliated Hospital of Tianjin University of Chinese Medicine,Tianjin(300073),China;Department of Endocrinology,Xiyuan Hospital,China Academy of Chinese Medical Sciences,Beijing(100091),China;Department of Endocrinology,Affiliated Hospital of Henan Academy of Traditional Chinese Medicine,Zhengzhou(450003),China
引用格式:
[1]QU Ling;LIANG Xiao-chun;TIAN Guo-qing;ZHANG Gai-li;WU Qun-li;HUANG Xiu-mei;CUI Ya-zhong;LIU Yu-ling;SHEN Zhu-fang;MA Guo-qing;LU Hao;LI Yi;JIANG Hong;YANG Xi-yan;ZHANG Guang-de;YANG Chen-hua-.Efficacy and Safety of Mulberry Twig Alkaloids Tablet for Treatment of Type 2 Diabetes:A Randomized,Double-Blind,Placebo-Controlled Multicenter Clinical Study)[J].中国结合医学杂志(英文版),2022(04):304-311
A类:
Alkaloids,Sangzhi,TAEs,GDs,ChiCTR2000038550
B类:
Efficacy,Safety,Mulberry,Twig,Tablet,Treatment,Type,Diabetes,Randomized,Double,Blind,Placebo,Controlled,Multicenter,Clinical,Study,Objective,To,assess,efficacy,safety,mulberry,twig,alkaloids,SZ,treatment,type,diabetes,randomized,double,blind,placebo,controlled,multicenter,clinical,trial,Methods,total,patients,were,receive,weeks,data,analysis,system,electronic,capture,central,randomization,was,used,dispensing,drugs,primary,outcome,glycosylated,hemoglobin,HbA1c,level,secondary,included,proportions,cases,fasting,blood,glucose,FBG,postprandial,PBG,area,under,curve,AUC0,2h,body,weight,mass,Adverse,events,severe,adverse,SAEs,related,gastrointestinal,disorders,pressure,routine,tests,liver,kidney,function,monitored,Results,Compared,baseline,respectively,higher,than,observed,values,changes,differed,significantly,between,groups,but,differences,not,incidence,rates,whereas,showed,Conclusion,effective,protocol,registered
AB值:
0.506878
相似文献
A trial of arbidol hydrochloride in adults with COVID-19
Zhao Jingya;Zhang Jinnong;Jin Yang;Tang Zhouping;Hu Ke;Sun Hui;Shi Mengmeng;Yang Qingyuan;Gu Peiyu;Guo Hongrong;Li Qi;Zhang Haiying;Li Chenghong;Yang Ming;Xiong Nian;Dong Xuan;Xu Juanjuan;Lin Fan;Wang Tao;Yang Chao;Huang Bo;Zhang Jingyi;Chen Shi;He Qiong;Zhou Min;Qu Jieming-Department of Pulmonary and Critical Care Medicine, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200025, China;Institute of Respiratory Diseases, School of Medicine, Shanghai Jiao Tong University, Shanghai 200025, China;Department of Emergency, Union Medical College Affiliated to Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430058, China;Department of Respiratory and Critical Care Medicine, Union Medical College Affiliated to Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430058, China;Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China;Department of Respiratory and Critical Care Medicine, Renmin Hospital, Wuhan University, Wuhan, Hubei 430060, China;Department of Endocrinology, Union Medical College Affiliated to Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430058, China;Department of Respiratory Medicine, Wuhan Bauhinia Hospital, Wuhan, Hubei 430062, China;Department of Respiratory Medicine, Guanggu Hospital District, The Third Hospital of Wuhan, Wuhan, Hubei 430074, China;Department of Respiratory and Critical Care Medicine, Puren Hospital, Wuhan University of Science and Technology, Wuhan, Hubei 430081, China;Department of Respiratory Medicine, The Third People’s Hospital of Hubei Province, Wuhan, Hubei 430030, China;Department of Respiratory Medicine, The Sixth General Hospital of Hubei Province, Wuhan, Hubei 430015, China;Tuberculosis Department of Chengdu Public Health Clinical Medical Center, Chengdu, Sichuan 610066, China;Department of Neurology, Wuhan Red Cross Hospital, Wuhan, Hubei 430015, China;Department of Tuberculosis, Jinyintan Hospital, Wuhan, Hubei 430048, China;Department of Cardiology, The Third People’s Hospital of Hubei Province, Wuhan, Hubei 430030, China
Dynamic changes of renal cortical blood perfusion before and after percutaneous transluminal renal artery stenting in patients with severe atherosclerotic renal artery stenosis
Ma Na;Li Yan;Wang Siyu;Li Mengpu;Li Yongjun;Ai Hu;Zhu Hui;Wang Yang;Guo Fajin;Ren Junhong-Department of Sonography, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Science, Beijing 100730, China;Department of Vascular Surgery, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Science, Beijing 100730, China;Department of Cardiology, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Science, Beijing 100730, China;Department of Nuclear Medicine, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Science, Beijing 100730, China;Department of Medical Research & Biometrics Center, National Center for Cardiovascular Diseases and Fuwai Hospital, CAMS and PUMC, Beijing 100037, China
Efficacy and safety of high-dose esomeprazole–amoxicillin dual therapy for Helicobacter pylori rescue treatment: a multicenter, prospective, randomized, controlled trial
Bi Hanxin;Chen Xingxing;Chen Yuxin;Zhao Xin;Wang Shasha;Wang Jiehong;Lyu Ting;Han Shuang;Lin Tao;Li Mingquan;Yuan Donghong;Liu Junye;Shi Yongquan-Xi’an Medical University, Xi’an, Shaanxi 710021, China;State Key Laboratory of Cancer Biology, National Clinical Research Center for Digestive Diseases and Xijing Hospital, Air Force Medical University, Xi’an, Shaanxi 710032, China;Department of Gastroenterology, Xianyang Central Hospital, Xianyang, Shaanxi 712000, China;Department of Gastroenterology, Affiliated Hospital of Shaanxi University of Chinese Medicine, Xianyang, Shaanxi 712000, China;Department of Gastroenterology, Shaanxi Nuclear Industry 215 Hospital, Xianyang, Shaanxi 712000, China;Department of Gastroenterology, Xi’an Red Cross Hospital, Xi’an, Shaanxi 710054, China;Department of Gastroenterology, Xi’an Daxing Hospital, Xi’an, Shaanxi 710082, China;Department of Gastroenterology, Yan’an People’s Hospital, Yan’an, Shaanxi 716000, China;Department of Gastroenterology, Yan’an University Affiliated Hospital, Yan’an, Shaanxi 716000, China;Department of Radiation Protective Medicine, Air Force Medical University, Xi’an, Shaanxi 710032, China
Effect and safety of anaprazole in the treatment of duodenal ulcers: a randomized, rabeprazole-controlled, phase III non-inferiority study
Zhu Huiyun;Pan Xue;Zhang Li;Sun Hongxin;Fan Huizhen;Pan Zhongwei;Huang Caibin;Shi Zhenwang;Ding Jin;Wang Qi;Du Yiqi;Lyu Nonghua;Li Zhaoshen-Department of Gastroenterology, Changhai Hospital of Navy Military Medical University, Shanghai 200433, China;Drug Clinical Trial Institution, Changhai Hospital of Navy Military Medical University, Shanghai 200433, China;Department of Gastroenterology, Yichun People’s Hospital, Yichun, Jiangxi 336028, China;Department of Gastroenterology, Meihekou Central Hospital, Meihekou, Jilin 135099, China;Department of Gastroenterology, The First Affiliated Hospital of Gannan Medical College, Ganzhou, Jiangxi 341001, China;Department of Gastroenterology, Hefei Second People’s Hospital, Hefei, Anhui 230011, China;Department of Gastroenterology, Jinhua Central Hospital, Jinhua, Zhejiang 321099, China;Department of Gastroenterology, Anqing Municipal Hospital, Anqing, Anhui 246004, China;Department of Gastroenterology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, China
Ginger-indirect moxibustion plus acupuncture versus acupuncture alone for chronic fatigue syndrome:a randomized controlled trial
MA Tingting;WU Jie;YANG Lijie;FENG Fen;YANG Huilin;ZHANG Jinhua;ZHONG Yanjin;NING Qing;HUANG Lirong;LIN Youbing;YAN Jue;CHEN Guiquan;HOU Tianshu;WANG Li;REN Yuanfang;TAN Jing-Center of Preventive Medicine,Hospital of Chengdu University of Traditional Chinese Medicine,Chengdu 610075,China;College of Acupuncture and Tuina,Chengdu University of Traditional Chinese Medicine,Chengdu 610075,China;Department of acupuncture,Center of Preventive Medicine,Affiliated TCM Hospital of Southwest Medical University,Luzhou 646600,China;Center of Preventive Medicine,Chengdu Integrated TCM and Western Medicine Hospital,Chengdu 610021,China;Center of Chinese Evidence-Based Medicine,Sichuan University West China Hospital,Chengdu 610041,China
Efficacy and safety of a sequential treatment with clearing heat and eliminating phlegm and tonifying Qi and activating blood circulation in treating acute ischemic stroke:study protocol for a randomized controlled trial
ZHOU Ziyi;WAN Can;ZHAO Yuanqi;LIU Xiangzhe;GAO Ying;AN Hongwei;LI Lejun;ZHANG Huili;YU Xiaofei;ZHANG Xinchun;WANG Huijuan;SHI Qing;WEI Chunhua;CHEN Jie;HUANG Wenguo;CHEN Junbin;HU Mingzhe;CAI Yefeng-Department of Neurology,Guangdong Provincial Hospital of Chinese Medicine,Guangzhou 510120,China;The Second Clinical College of Guangzhou University of Chinese Medicine,Guangzhou 510120,China;the Second Clinical College of Guangzhou University of Chinese Medicine,Guangzhou 510120,China;Department of Neurology,The First Affiliated Hospital of Henan University of Traditional Chinese Medicine,Zhengzhou 450000,China;Department of Neurology,Shenyang Second Hospital of Traditional Chinese Medicine,Shenyang 110100,China;Department of Neurology and Stroke Center,Dongzhimen Hospital affiliated to Beijing University of Chinese Medicine,Beijing 100700,China;Department of Neurology,Liuzhou Traditional Chinese Medical Hospital,Liuzhou 545001,China;Department of Neurology,Wuxi Traditional Chinese Medicine Hospital,Wuxi 214071,China;Department of Neurology,Qinhuangdao City Hospital of Traditional Chinese Medicine,Qinhuangdao 066000,China;Department of Neurology,Shanghai Shuguang Hospital,Shanghai 200120,China;Department of Neurology,the Second Hospital of Hebei Medical University,Shijiazhuang 050000,China;Department of Neurology,Jiangmen Wuyi Hospital of Traditional Chinese Medicine,Jiangmen 529000,China;Department of Neurology,Nanshi Hospital Affiliated to Henan University,Nanyang 473065,China;Department of Neurology,Shanxi Province Hospital of Traditional Chinese Medicine,Xi'an 710003,China;Department of Neurology,Maoming Hospital of Traditional Chinese Medicine,Maoming 525000,China;Department of Neurology,the Northern Guangdong People's Hospital,Shaoguan 512025,China;Department of Neurology, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan 250014, China
Wenshen Jianpi recipe(温肾健脾方)induced immune reconstruction and redistribution of natural killer cell subsets in immunological non-responders of human immunodeficiency virus/acquired immune deficiency syndrome:a randomized controlled trial
TAO Zhuang;WANG Jian;CHEN Xin;LI Yonghong;YAN Yuguang;ZHANG Ao;ZOU Wen;LIU Ying-Research Center of AIDS Treatment with Traditional Chinese Medicine,China Academy of Chinese Medical Sciences,Beijing 100700,China;Institute of Basic Theory for Chinese Medicine,China Academy of Chinese Medical Sciences,Beijing 100700,China;Department of Integrated Traditional Chinese and Wetern Medicine,Kunming Hospital of Traditional Chinese Medicine,Kunming 650000,China;Department of Infection,No.6 People's Hospital of Shenyang City,Shenyang 110006,China;University of Chinese Academy of SoCIal SCIences,Beijing,100102,China
Efficacy and Safety of Ixekizumab in Chinese Patients With Moderate-to-Severe Plaque Psoriasis: 60-Week Results From a Phase 3 Study
Li Xia;Zheng Jie;Pan Wei-Li;Zheng Min;Lu Yan;Li Fu-Qiu;Ding Yang-Feng;Zhang Jian-Zhong;Li Hong-Ying;Rui Wen-Long-Department of Dermatology, Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai 200025, China;Department of Dermatology, Zhejiang Provincial People’s Hospital, Hangzhou, Zhejiang 314408, China;Department of Dermatology, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang 310003, China;Department of Dermatology, Jiangsu Province Hospital, Nanjing, Jiangsu 210029, China;Department of Dermatology, The Second Hospital of Jilin University, Changchun, Jilin 130041, China;Department of Dermatology, Shanghai Skin Disease Hospital, Shanghai 130041, China;Department of Dermatology, Peking University People’s Hospital, Beijing 130041, China;China Drug Development and Medical Affairs Center, Eli Lilly and Company, Shanghai 200041, China
Laboratory Safety of Dupilumab, and Its Effect on Inflammatory Biomarkers, in Chinese Adults With Moderate-to-Severe Atopic Dermatitis: An Analysis of a Randomized, Double-Blind Phase III Study
Zhao Yan;Wu Li-Ming;Lu Qian-Jin;Gao Xing-Hua;Zhu Xiao-Hong;Yao Xu;Li Lin-Feng;Li Wei;Ding Yang-Feng;Song Zhi-Qiang;Liu Ling-Ling;Dang Ning-Ning;Zhang Chun-Lei;Liu Xiao-Ming;Gu Jun;Wang Jin-Yan;Geng Song-Mei;Liu Quan-Zhong;Guo Yi-Feng;Dong Li;Li Shelley;Xu Christine;O’Malley John T.;Laws Elizabeth;Amin Nikhil;Bansal Ashish;Wang Min;Zhang Jian-Zhong-Department of Dermatology, Peking University People’s Hospital, Beijing 100044, China;Hangzhou First People’s Hospital, Hangzhou, Zhejiang 310006, China;The Second Xiangya Hospital of Central South University, Changsha, Hunan 410011, China;The First Hospital of China Medical University, Shenyang, Liaoning 110001, China;Wuxi Second People’s Hospital, Wuxi, Jiangsu 214002, China;Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences, Nanjing, Jiangsu 210042, China;Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China;Huashan Hospital, Fudan University, Shanghai 200040, China;Shanghai Skin Disease Hospital, Shanghai 200040, China;The Southwest Hospital of AMU, Chongqing 400038, China;Peking University First Hospital, Beijing 100034, China;Jinan Central Hospital, Jinan, Shandong 250013, China;Peking University Third Hospital, Beijing 100191, China;University of Hong Kong-Shenzhen Hospital, Shenzhen, Guangdong 518040, China;Changhai Hospital of Shanghai, Shanghai 200433, China;Ningbo No. 2 Hospital, Ningbo, Zhejiang 315099, China;The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi 710004, China;Tianjin Medical University General Hospital, Tianjin 300052, China;Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai 200092, China;Research & Development, Sanofi, Bridgewater, NJ 08807, USA; Development, Regeneron, Tarrytown, NY 10591, USA;Medical, Sanofi China, Shanghai 200040, China
The Correlation Between Decreased Ornithine Level and Alleviation of Rheumatoid Arthritis Patients Assessed by a Randomized,Placebo-Controlled,Double-Blind Clinical Trial of Sinomenine
Ying Shi;Hu-Dan Pan;Jian-Lin Wu;Qing-Hua Zou;Xin-Yi Xie;Hong-Gang Li;Hua Zhou;Xi-Qing Bian;Wen-Fei Leng;Can-Jian Wang;Ya-Feng Wang;Yong-Fei Fang;Liang Liu-Department of Rheumatology,The Southwest Hospital of Army Military Medical University,Chongqing 400038,China;State Key Laboratory of Dampness Syndrome Chinese Medicine,The Second Affiliated Hospital of Guangzhou University of Chinese Medicine,Guangzhou 510000,China;State Key Laboratory of Quality Research in Chinese Medicine&Macau Institute for Applied Research in Medicine and Health,Macau University of Science and Technology,Macao 999078,China;People's Hospital of Changshou Chongqing,Chongqing 401220,China;Traditional Chinese Medicine Hospital Dianjiang Chongqing,Chongqing 408300,China;Medical Management Center,World Federation of Chinese Medicine Societies,Beijing 100101,China
机标中图分类号,由域田数据科技根据网络公开资料自动分析生成,仅供学习研究参考。